Experimental therapy with 9-[2-(Phosphonomethoxy)ethyl]-2, 6-diaminopurine (PMEDAP): Origin of resistance

Folia Biologica

Volumn 53, Issue 3, 2007, Pages 79-84

  Zápotocký, Michal ^a   Hanzalova J ^a   Starkova J ^a   Votruba, I ^b   Holy A ^b   Otova B ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

Author keywords

MRP4; MRP5; PMEDAP resistance

Indexed keywords

2,6 DIAMINO 9 (2 PHOSPHONOMETHOXYETHYL)PURINE; MULTIDRUG RESISTANCE PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 5;

ANIMAL EXPERIMENT; ARTICLE; DRUG SENSITIVITY; GENE ACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LONG TERM CARE; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; T CELL LYMPHOMA;

RATTUS;

EID: 34250882212     PISSN: 00155500     EISSN: 25337602     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Birkuš, G., Votruba, I., Holý, A., Otová, B. (1999) PMEApp as a substrate toward replicative DNA polymerases δ, and ε*. Biochem. Pharamacol. 58, 487-492.
2. Bobková, K., Otová, B., Marinov, I., Mandys, V., Panczak, A., Votruba, I. Holý, A. (2000) Anticancer effect of PMEDAP - monitoring of apoptosis. Anticancer Res. 20, 1041-1048.
3. Bobková, K., Gut, I., Mandys, V., Holý, A., Votruba, I., Otová, B. (2001) Antitumour activity of a combined treatment with PMEDAP and docetaxel in the Prague inbred Sprague-Dawley/Cub rat strain bearing T-cell lymphoma. Anticancer Res. 21, 2725-2732.
4. Franěk, F., Holý, A., Votruba, I., Eckschlager, T. (1998) Modulation of cell cycle progression and of antibody production in mouse hybridomas by a nucleotide analogue. Cytotechnology 28, 65-72.
5. Gauthier, E. R., Madison, S. D., Michel, R. N. (1997) Rapid RNA isolation without the use of commercial kits: application to small tissue samples. Pflugers Arch. 433, 664-668.
6. Hatse, S., De Clercq, E., Balzarini J. (1998) Enhanced 9-(2-phosphonylmethoxy-ethyl)adenine secretion by a specific, indomethacine-sensitive efflux pump in a mutant 9-(2-phosphonylmethoxyethyl)adenine-resistant human erythroleukemia K562 cell line. Mol. Pharmacol. 54, 907-917.
7. Holý, A., Rosenberg, I., Dvořáková, H. (1989) Synthesis of N-(2-phosphonylmethoxy-ethyl) derivatives of heterocyclic bases. Collect. Czech. Chem. Commun. 54, 2190-2210.
8. Holý, A. (2003) Phosphonomethoxyalkyl analogs of nucleotides. Curr. Pharm. Des. 9, 2567-2592.
9. Horská, K., Votruba, I., Holý, A. (2006) Interaction of phosphates of the acyclic nucleoside phosphonates with NDP kinase from yeast and bovine liver. Collect. Czech. Chem. Commun. 71, 35-43.
10. Kramata, P., Votruba, I., Otová, B., Holý, A. (1996) Different inhibitory potencies of acyclic phosphonomethoxyalkyl nucleotide analogs toward DNA polymerases δ and ε. Mol. Pharmacol. 49, 1005-1011.
11. Kramata, P., Downey, K. M., Paborsky, L. R. (1998) Incorporation and excision of 9-(2-phosphonylmethoxyethyl) guanine by DNA polymerace δ and ε in vitro. J. Biol. Chem. 273, 21966-21971.
12. Krejčová, R., Horská, K., Votruba, I., Holý, A. (2000) Phosphorylation of purine phosphonomethoxyalkyl derivatives by mitochondrial AMP kinase (AK2 type) from L1210 cells. Collect. Czech. Chem. Commun. 65, 1653-1668.
13. Lee, K., Klein-Szanto, A. J. P., Kruh, G. D. (2000) Analysis of the MRP4 drug resistant profile in transfected NIH3T3. J. Natl. Cancer Inst. 92, 1934-1940.
14. Morrison, T. M., Weiss, J. J., Wittwer, C. T. (1998) Quantification of low-copy transcripts by continuous SYBR green I monitoring during amplification. Biotechniques 24, 954-962.
15. Otová, B., Zídek, Z., Holý, A., Votruba, I., Sladká, M., Marinov, I., Lešková, V. (1997) Antitumor activity of novel purine acyclic nucleotide analogs PMEA and PMEDAP. In vivo 11, 163-168.
16. Otová, B., Francová, K., Franěk, F., Koutnik, P., Votruba, I., Holý, A., Sladká, M., Schramlová, J. (1999) 9-[2-(Phosphonomethoxy)ethyl]-2,6-diaminopurine(PMEDAP) - a potential drug against hematological malignancies - induces apoptosis. Anticancer Res. 19, 3173-3182.
17. Otová, B., Sladká, M., Damoiseaux, J., Panczak, A., Mandys, V., Marinov, I. (2002) Relevant animal model of human lymphoblastic leukaemia/lymphoma - spontaneous T-cell lymphomas in an inbred Sprague-Dawley rat strain (SD/Cub). Folia Biol. (Praha) 48, 213-226.
18. Sampath, J., Adachi, M., Hatse, S., Naesens, L., Balzarini, J., Flatley, R., Matherly, L., Schuetz, J. (2002) Role of MRP4 and MRP5 in biology and chemotherapy. AAPS PharmSci. 4, 1-9.
19. Schuetz, J., Connelly M., Sun, D., Paibir, S., Flynn, P. M., Srinivaa, R. V., Kumar, A., Fridland, A. (1999) MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drug. Nat. Med. 5, 1048-1051.
20. Veselý, J., Merta, A., Votruba, I., Holý, A., Rosenberg, I. (1990) The cytostatic effects and mechanism of action of antiviral acyclic adenine nucleotide analogs in L-1210 mouse leukemic cells. Neoplasma 37, 105-110.
21. Wijnholds, J., Mol, C. A., van Deemter, L., de Haas, M., Scheffer, G. L., Baas, F., Beijnen, J. H., Scheper, R., Hatse, S., De Clercq, E., Balzarini, J., Borst, P. (2000) Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc. Natl. Acad. Sci. USA 97, 7476-7481.